Epigenic Therapeutics Secures $60 Million Series B Funding to Propel Epigenetic Medicine Development

Epigenic Therapeutics Completes $60 Million Series B Financing

In a significant development for the biotechnology sector, Epigenic Therapeutics, a clinical-stage company, has announced the successful completion of a $60 million Series B funding round. This financing was spearheaded by Lapam Capital, with contributions from existing investors Qiming Venture Partners and OrbiMed, along with new backing from the investment group IFSC and a notable industry firm. This substantial funding is set to enhance the ongoing clinical trials of two pivotal therapies: EPI-003 aimed at treating chronic hepatitis B and EPI-001 for managing hypercholesterolemia. Furthermore, the capital will enable the progress of multiple preclinical projects while bolstering the company's technology platforms.

Epigenic Therapeutics stands at the cutting edge of innovative drug development, focusing on gene modulation therapies aimed at addressing a range of chronic ailments by regulating the epigenome. Central to its strategy is the proprietary EPIREG™ technology, which offers a safe and efficient method for the targeted silencing of genes via DNA methylation and histone modification—traits that distinguish it from more traditional gene-editing techniques that often involve DNA cleavage. The utilization of EPIREG™ presents a less risk-prone alternative for patients suffering from chronic conditions, thereby addressing significant safety concerns typically associated with conventional approaches.

The company’s advancements further include EpiTax™, a sophisticated in-vivo LNP (lipid nanoparticle) delivery system designed for the precise transportation of EPIREG™ mechanisms to the liver and various other organs. This enhancement not only broadens the applicability of the EPIREG™ platform across a multitude of disease areas but also strengthens Epigenic's competitive positioning within the biotechnology landscape.

Additionally, the firm has developed the AIAID™ platform, which enhances molecular design, target selection, and modulation capabilities essential for epigenetic medicine. This platform incorporates a self-generated foundational model specific to epigenetics and is designed to provide crucial core data and algorithmic support. The collaborative virtual lab inherent in AIAID™ autonomously conducts various tasks such as discovering and investigating targets, predicting accessibility, designing sgRNAs, and performing intricate analyses across multiple omics categories. Moreover, it leverages AI technologies for protein design and evolution, expediting the discovery and optimization processes of EPIREG™ products.

Dr. Bob Zhang, Co-founder and CEO of Epigenic Therapeutics, expressed gratitude towards both newly-acquired and existing investors, emphasizing the importance of their trust and support. He remarked that the firm has made palpable progress in epigenetic modulation technologies since its inception. “Our mission is to propel the clinical development of our fundamental therapies to ensure patients receive safe and effective treatments at the earliest possible stage,” he noted.

Mr. Zhihua Yu, Chairman of Lapam Capital, highlighted the vast potential of epigenetic drug development, affirming Epigenic’s substantial technological advantages. He stated that the combination of the EPIREG™ platform and EpiTax™ delivery method positions Epigenic uniquely within the market, and with this funding, the company is poised for further breakthroughs in both clinical development and tech innovation.

About Epigenic Therapeutics

Founded in 2021, Epigenic Therapeutics is committed to pioneering the next generation of gene modulation therapies. With a focus on various diseases, it coordinates comprehensive research with multiple candidates targeting metabolic, cardiovascular, viral hepatitis, ocular, and autoimmune diseases.

About Lapam Capital

Lapam Capital, based in Beijing, is a leading venture capital firm in the biomedical domain, managing significant funds invested in innovative pharmaceuticals and medical devices. Its experienced team has facilitated investments in numerous enterprises, making substantial contributions to the industry's growth.

About Qiming Venture Partners

Since its establishment in 2006, Qiming has focused on early and growth-stage investments in superior technology and healthcare firms, facilitating over 580 investments and achieving notable exits for numerous portfolio companies.

About OrbiMed

With a comprehensive approach across healthcare sectors, OrbiMed, managing over $17 billion, invests in companies ranging from start-ups to established multinational corporations.

About IFSC

IFSC concentrates on life sciences investments, driven by a philosophy of value investing rooted in basic science, striving to address unmet clinical needs in order to advance human health.